Innovent Biologics

Innovent Biologics To empower patients worldwide with affordable, high-quality biopharmaceuticals Innovent has launched 17 products in the market.

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. It h

as 1 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

09/06/2026

Honored to share Innovent's story with the global metabolic community at .

Throughout the conference, our corporate video has been featured on ADA TV, a great opportunity to showcase Innovent's mission and innovative work to a global audience.

At the 2026 ADA Scientific Sessions, we presented multiple oral reports on Mazdutide, along with early clinical and preclinical data on our next‑generation weight management and metabolic pipeline, including IBI3032 (once‑daily oral GLP‑1 small molecule), IBI3042 (once‑weekly oral GLP‑1 small molecule), IBI3040 (amylin analogue), and IBI3046 (INHBE siRNA). Innovent is building a differentiated, multi‑tiered innovation portfolio in global weight management and related metabolic comorbidities.

Our mission remains to empower patients globally with affordable, high-quality biopharmaceuticals, and we aspire to provide more comprehensive, science-driven and long-term treatment options for people living with obesity and metabolic diseases worldwide.

Watch our story here:
Full version: https://www.youtube.com/watch?v=fr6IQb8wkMI

At the Scientific Sessions 2026, Innovent presented a broad metabolic and obesity portfolio, including three oral pres...
09/06/2026

At the Scientific Sessions 2026, Innovent presented a broad metabolic and obesity portfolio, including three oral presentations of mazdutide across adults and adolescents with obesity and type 2 diabetes, along with early data from four next-generation pipeline programs.

The early-stage assets include oral GLP-1 receptor agonists designed to improve convenience and accessibility, a novel amylin analog with potential to enhance weight-loss outcomes, and an INHBE-targeting siRNA aimed at enabling durable, infrequent dosing with sustained fat loss.

Together, these programs reflect a differentiated strategy that extends beyond weight reduction to address tolerability, durability, dosing convenience, and broader cardiometabolic health. All are key unmet needs in obesity and metabolic disease care.

Learn more about Innovent's pipeline presented at ADA 2026: https://www.prnewswire.com/news-releases/2026-ada--innovent-presents-multiple-clinical-and-preclinical-results-of-next-generation-obesity--metabolic-pipeline-302793636.html

We're pleased to share that Innovent has presented first-in-China Phase 1b results for mazdutide in adolescents with obe...
08/06/2026

We're pleased to share that Innovent has presented first-in-China Phase 1b results for mazdutide in adolescents with obesity as an oral presentation at the Scientific Sessions.

The study demonstrated that once-weekly mazdutide was generally well tolerated in Chinese adolescents and showed encouraging effects on body weight, BMI, and a range of cardiometabolic measures. The safety profile was consistent with previous studies, supporting the continued clinical development of mazdutide in younger patient populations.

Adolescent obesity is an increasingly urgent global health challenge, with excess weight in childhood often associated with a higher risk of long-term metabolic and cardiovascular complications. Despite the growing need, treatment options for adolescents remain limited in many markets, highlighting the importance of developing effective and evidence-based interventions for this population.

Building on these results, Innovent has initiated a registrational Phase 3 study of mazdutide in adolescents with obesity. The program represents an important step toward expanding treatment options and addressing a significant unmet need in obesity care at an earlier stage of life.

Learn more about the Phase 1b results and the ongoing development of mazdutide in adolescent obesity: https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=602

Innovent has presented Phase 3 DREAMS-3 results at the Scientific Sessions, marking the first head-to-head study of a ...
08/06/2026

Innovent has presented Phase 3 DREAMS-3 results at the Scientific Sessions, marking the first head-to-head study of a globally approved dual glucagon (GCG)/GLP-1 receptor agonist versus semaglutide.

The study evaluated mazdutide in adults living with both type 2 diabetes and obesity, demonstrating superior outcomes across key measures of glycemic control, weight management, and cardiometabolic health compared with semaglutide. Mazdutide was generally well tolerated, with a safety profile consistent with previous studies.

The results highlight the potential of dual GCG/GLP-1 receptor agonism to address two closely linked chronic conditions through a single therapeutic approach. As the prevalence of type 2 diabetes and obesity continues to rise globally, effective treatments that can simultaneously improve glucose control, support meaningful weight loss, and address broader metabolic risk factors are becoming increasingly important.

We look forward to following the continued development of mazdutide and its potential to expand treatment options for people living with diabetes, obesity, and related metabolic diseases.

Learn more about the DREAMS-3 results presented at : https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=604

We're excited to share that Innovent's Phase 3 GLORY-2 study of mazdutide 9 mg, a first-in-class dual glucagon (GCG)/GLP...
08/06/2026

We're excited to share that Innovent's Phase 3 GLORY-2 study of mazdutide 9 mg, a first-in-class dual glucagon (GCG)/GLP-1 receptor agonist for chronic weight management, has been simultaneously published in the JAMA and selected for oral presentation at the Scientific Sessions.

The Phase 3 results demonstrated the potential of mazdutide to deliver clinically meaningful and sustained weight loss, alongside broader metabolic benefits, in adults with obesity. The treatment was generally well tolerated and showed a safety profile consistent with previous studies.

Simultaneous publication in a leading medical journal and presentation at one of the world's premier diabetes and metabolic disease conferences highlights the growing global recognition of innovative metabolic medicines developed in China.

As obesity continues to represent a major global health challenge, these findings underscore the potential of next-generation therapies to expand treatment options and improve long-term outcomes for patients living with obesity and related metabolic conditions.

Learn more about the GLORY-2 study and the latest mazdutide data: https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=603

Innovent's arcotatug tavatecan (IBI343/TAK-921) has met the primary endpoint of the global Phase 3 G-HOPE-001 study and ...
05/06/2026

Innovent's arcotatug tavatecan (IBI343/TAK-921) has met the primary endpoint of the global Phase 3 G-HOPE-001 study and received NDA acceptance with priority review from China's NMPA.

Arcotatug tavatecan is a CLDN18.2-targeted ADC developed for patients with CLDN18.2-positive gastric and gastroesophageal junction adenocarcinoma (G/GEJA). The therapy demonstrated significant efficacy with a manageable safety profile in previously treated patients and has become the first CLDN18.2-targeted ADC worldwide to reach regulatory submission.

For patients facing limited treatment options after multiple lines of therapy, this milestone represents an important advance in biomarker-driven gastrointestinal cancer care and highlights the growing potential of precision oncology to address unmet medical needs.

We look forward to seeing the full Phase 3 data presented at upcoming scientific meetings and to following the continued progress of this global co-development program between Innovent and Takeda. https://en.prnasia.com/releases/global/world-s-first-cldn18-2-adc-for-regulatory-review-innovent-biologics-announces-ibi343-arcotatug-tavatecan-met-primary-endpoint-in-international-phase-3-study-in-advanced-refractory-gastric-cancer-and-nda-accepted-by-china-nmpa-535928.shtml

At , Innovent presented long-term follow-up data on IBI363 (TAK-928), a first-in-class PD-1/IL-2α-bias bispecific fusio...
02/06/2026

At , Innovent presented long-term follow-up data on IBI363 (TAK-928), a first-in-class PD-1/IL-2α-bias bispecific fusion protein, in advanced NSCLC patients whose disease had progressed following prior immunotherapy, a setting where meaningful treatment options remain limited.

The updated results are encouraging, demonstrating durable clinical benefit over extended follow-up in both IO-resistant squamous NSCLC and wild-type adenocarcinoma NSCLC. Particularly noteworthy signals were observed in patients with a smoking history, further supporting the potential of this novel approach in difficult-to-treat populations.

Equally important, the safety profile remained favorable with longer follow-up, supporting the feasibility of sustained treatment, an important consideration for patients with resistant disease.

The program has now advanced into the global Phase 3 MarsLight-11 study in IO-resistant squamous NSCLC, with a Phase 3 study in IO-resistant non-squamous NSCLC planned pending regulatory alignment. This marks an important milestone in the global co-development effort between Innovent and Takeda.

We invite you to learn more about the long-term findings presented at ASCO 2026 and the potential implications for patients with IO-resistant NSCLC: https://www.prnewswire.com/news-releases/2026-asco--innovent-presents-long-term-follow-up-results-from-the-poc-study-of-ibi363-tak-928-pd-1il-2-bias-bispecific-fusion-protein-showing-robust-survival-benefits-in-advanced-immunotherapy-resistant-non-small-cell-lung-302786450.html?tc=eml_cleartime

At , Innovent shared preliminary data on IBI363 (TAK-928), a first-in-class PD-1/IL-2α-bias bispecific fusion protein, ...
02/06/2026

At , Innovent shared preliminary data on IBI363 (TAK-928), a first-in-class PD-1/IL-2α-bias bispecific fusion protein, in first-line advanced NSCLC patients with PD-L1-negative or low-expression tumors, a population that has historically faced limited treatment options.

The early results are encouraging, demonstrating promising clinical activity in combination with chemotherapy across multiple histologies. Equally important, the safety profile appears supportive of continued treatment, an important consideration for achieving durable patient benefit.

The program has now advanced into a head-to-head study against pembrolizumab plus chemotherapy, marking an important next step in evaluating its potential role in the first-line setting. We look forward to following the progress of this global co-development effort between Innovent and Takeda.

Learn more about the data presented at ASCO 2026 and the potential implications for patients with PD-L1-negative or low-expression NSCLC, and explore the findings: https://www.prnewswire.com/news-releases/2026-asco--innovent-presents-preliminary-poc-data-of-ibi363-tak-928-pd-1il-2-bias-bispecific-fusion-protein-in-first-line-advanced-nsclc-302786452.html?tc=eml_cleartime

Today's announcement of a strategic collaboration between Innovent Biologics and Pfizer marks a significant step in adva...
29/05/2026

Today's announcement of a strategic collaboration between Innovent Biologics and Pfizer marks a significant step in advancing a broad portfolio of 12 investigational oncology programs, including antibody-drug conjugates and multi-specific antibodies.

By bringing together complementary expertise and capabilities, the partnership is designed to support the efficient advancement of promising candidates through key stages of development while leveraging the strengths of both organizations.

We look forward to working alongside Pfizer on this portfolio, combining scientific innovation with global development and commercialization expertise to create a strong foundation for advancing these programs and expanding their potential impact for patients worldwide.

Learn more about our collaboration: https://en.prnasia.com/releases/global/innovent-biologics-and-pfizer-enter-global-strategic-collaboration-to-accelerate-development-of-innovative-oncology-medicines-534952.shtml

At ASCO this year, Innovent presented updated long-term data from the Phase 1 proof-of-concept study of IBI363 (Takeda R...
22/05/2026

At ASCO this year, Innovent presented updated long-term data from the Phase 1 proof-of-concept study of IBI363 (Takeda R&D code: TAK-928), a first-in-class PD-1/IL-2α-bias bispecific fusion protein, in immunotherapy-resistant advanced non-small cell lung cancer.

With longer follow-up from the China-based PoC study, IBI363 continued to demonstrate a manageable long-term safety profile, together with durable overall survival benefits observed in both squamous and non-squamous NSCLC. These findings add to the growing evidence supporting its dual mechanism, combining immune checkpoint blockade with cytokine agonism, as a potential driver of sustained clinical benefit in this hard-to-treat population.
Building on these results, IBI363 has now entered a global Phase 3 study (MarsLight-11) in IO-resistant squamous NSCLC, with the study design also being presented at ASCO. Subject to regulatory discussions, a global Phase 3 study in IO-resistant non-squamous NSCLC is also planned. Together, these milestones reflect continued progress toward evaluating IBI363 in a broader global lung cancer population.https://www.prnewswire.com/news-releases/2026-asco-abstract-highlights-innovent-biologics-ibi363-pd-1il-2-bias-bispecific-fusion-protein-demonstrates-robust-survival-benefits-in-long-term-follow-up-of-poc-study-in-advanced-immunotherapy-resistant-non-small-cell-lun-302779647.html


Address

Suzhou
215028

Telephone

+8651269566088

Website

Alerts

Be the first to know and let us send you an email when Innovent Biologics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Innovent Biologics:

Shortcuts

Share

Category